Positions

Overview

  • My medical training at the University of Heidelberg included doctoral research at the Max Plank Institute for Medical Research in Heidelberg involving the primary sequencing of the red blood cell enzyme Glutathione Reductase. My hematology/oncology fellowship training at the University of Alabama at Birmingham included laboratory investigation in the immune mediated platelet destruction (ITP), as well as, the generation of human monoclonal auto-antibodies from splenic B-cells derived from ITP patients. My NIH funded RO1 research in ITP evolved into a translational research interest in the treatment of ITP – to the use of anti-CD20 MoAb Rituximab in the treatment of ITP and subsequently as one of the lead USA investigators for the pivotal trial leading to the FDA approval of the recombinant TPO receptor agonist Elthrombopag for the treatment of ITP.

    My translational research training involved the study of monoclonal antibodies directed against cancer associated target antigens. I have been the PI or co-PI of a number of breakthrough first-in-human clinical trials of mouse, chimeric and humanized anti-tumor monoclonal antibodies conducted at UAB. My laboratory conducted the initial study demonstrating the complimentary role of anti-EGFR MoAb and radiation therapy, and these observations lead to the pivotal RTOG trial and FDA approval of Erbitux/RT for the treatment of locally advanced Head/Neck cancer. As part of my translational research laboratory investigations, I developed and subsequently patented the first mirror-image anti-Id vaccine that mimics GD2 ganglioside antigen, highly expressed on certain tumors including melanoma and neuroblastoma.

    Over the past 25 years I have been involved in the development, conduct and oversight of clinical trials involving monoclonal antibodies, genetically engineered vaccine, anti-Id vaccines, novel small molecules and various cytotoxic chemotherapies, including practice changing therapies e.g. Eltrombopag in ITP, Gemzar/Abraxane in pancreatic cancer, Apalutamide in prostate cancer. In 2015, I established and led the Phase 1 drug development program at UAB and worked on over 30 first in human targeted therapy molecules. In addition, I led the establishment of a Clinical Investigator Training Program that trained 60 junior faculty into clinical investigators over a 2yr period. This works continues at the Aga Khan University in Nairobi through an ASCO Innovations Award.

    Development work has been an important part of my career. Over a 2 year period I paid 3 visits to the high mountain region of Gorno Badakshan Oblast in Tajikistan. In collaboration with the Aga Khan Health Services, I established the first ever breast cancer screening program in the region and laid the foundation for the clinical care pathway for the early detection and treatment of breast cancer. Similarly, in March, 2021, I led a major effort to bring colon cancer awareness to the general community, including employees at 40 major corporations and clinicians in Kenya.

    In 2020, I moved to the Aga Khan University in Nairobi, Kenya, to establish a Department of Hematology-Oncology and a Cancer Center, a matrix organization dedicated to cancer research. During the Covid pandemic the Cancer Center’s Clinical Research Unit (CRU) established itself as a leader in Covid-related clinical trials, garnered the highest enrollment in Africa for a study of Tociluzumab in severe Covid pneumonia, and I am the PI of a low dose radiotherapy trial for severe Covid pneumonia. In 2021 the CRU has been selected to conduct 3 oncology clinical trials using novel targeting agents, a first in sub Saharan Africa .
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 First-In-Human Phase 1 Clinical Trials – A Single-Center Experience In The Era Of Modern OncotherapeuticsScientific Reports.  10. 2020
    2020 Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings 2020
    2020 Clinical Investigator Training Program (CITP) – A practical and pragmatic approach to conveying clinical investigator competencies and training to busy cliniciansContemporary Clinical Trials Communications.  19. 2020
    2020 First-In-Human Phase 1 Clinical Trials - A Single-Center Experience In The Era Of Modern OncotherapeuticsScientific Reports.  10:7935-7935. 2020
    2020 TBCRC 002: A phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancerBreast Cancer Research.  22. 2020
    2019 Bridging the Gap in Training and Clinical Practice in Sub-Saharan AfricaCurrent Breast Cancer Reports.  11:158-169. 2019
    2019 Promoting Breast Cancer Awareness and Clinical Breast Examination in the LMIC: Experiences from Tajikistan, Pakistan and KenyaCurrent Breast Cancer Reports.  11:152-157. 2019
    2019 Outcomes of Gastrointestinal cancers treated on Phase 1 clinical trials at O'Neal Comprehensive Cancer CenterAnnals of Oncology.  30:iv66. 2019
    2019 Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 studyAnnals of Oncology.  30:iv124. 2019
    2019 Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology.  83:551-559. 2019
    2019 Breast Cancer knowledge, perceptions and practices in a rural Community in Coastal KenyaBMC Public Health.  19. 2019
    2019 Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND studyAmerican Journal of Hematology.  94:200-208. 2019
    2018 Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical modelsNature Communications.  9. 2018
    2018 So You want to be a principal investigatorJournal of Oncology Practice.  14:e384-e392. 2018
    2018 Promoting clinical breast evaluations in a lower middle-income country setting: An approach toward achieving a sustainable breast health programJournal of Global Oncology.  2018. 2018
    2018 Ethnicity and breast cancer characteristics in KenyaBreast Cancer Research and Treatment.  167:425-437. 2018
    2018 Nano and microbubble systems for on-demand cancer drug deliveryCurrent Nanoscience.  14:33-41. 2018
    2017 Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: Final results of the EXTEND studyBlood.  130:2527-2536. 2017
    2017 Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamideAnnals of Oncology.  28:2264-2271. 2017
    2017 Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisoneClinical Cancer Research.  23:3544-3551. 2017
    2017 Academic cancer center phase i program development 2017
    2016 Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia 2016
    2016 Breast camps for awareness and early diagnosis of breast cancer in countries with limited resources: A multidisciplinary model from Kenya 2016
    2016 Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patientsCancer Chemotherapy and Pharmacology.  78:509-515. 2016
    2016 Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trialAnnals of Oncology.  27:1041-1047. 2016
    2016 A community-oriented approach to breast cancer in a low-resource setting: Improving awareness, early detection and treatment of breast cancer in Tajikistan 2016
    2015 Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC)Cancer Chemotherapy and Pharmacology.  76:949-955. 2015
    2015 EMERGE: A randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB - Expressing breast cancerJournal of Clinical Oncology.  33:1609-1619. 2015
    2015 SPIRITT: A randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancerClinical Colorectal Cancer.  14:72-80. 2015
    2014 Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancerJournal of Clinical Oncology.  32:3840-3847. 2014
    2014 Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancerJournal of Clinical Oncology.  32:3619-3625. 2014
    2014 Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya 2014
    2014 A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancerClinical Cancer Research.  20:3581-3588. 2014
    2014 A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumorsAnnals of Oncology.  25:1416-1421. 2014
    2014 A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancerCancer Medicine.  3:988-997. 2014
    2014 Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community settingCurrent Medical Research and Opinion.  30:529-536. 2014
    2014 Severe neutropenia and relative dose intensity among patients <65 and ≥65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapySupportive Care in Cancer.  22:1833-1841. 2014
    2013 Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancerClinical Colorectal Cancer.  12:218-222. 2013
    2013 Breast cancer diagnosis in a resource poor environment through a collaborative multidisciplinary approach: The Kenyan experienceJournal of Clinical Pathology.  66:307-311. 2013
    2013 Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)British Journal of Haematology.  160:538-546. 2013
    2013 Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-term, open-label EXTEND studyBlood.  121:537-545. 2013
    2013 Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineNew England Journal of Medicine.  369:1691-1703. 2013
    2013 Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: A phase I studyBritish Journal of Haematology.  162:693-701. 2013
    2013 Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancerCancer Medicine.  2:925-932. 2013
    2013 Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-term, open-label EXTEND study 2013
    2012 Therapeutic optimization of aromatase inhibitor-associated arthralgia: Etiology, onset, resolution, and symptom management in early breast cancerCommunity Oncology.  9:94-102. 2012
    2012 Phase I study of bosutinib, a Src/Abl tyrosine kinase inhibitor, administered to patients with advanced solid tumorsClinical Cancer Research.  18:1092-1100. 2012
    2011 Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trialJournal of Clinical Oncology.  29:3877-3884. 2011
    2011 Abiraterone and increased survival in metastatic prostate cancerNew England Journal of Medicine.  364:1995-2005. 2011
    2011 Eltrombopag for chronic immune thrombocytopenia - Authors' reply 2011
    2011 Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study 2011
    2011 Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study (Lancet (2011) 377, (393-402)) 2011
    2011 Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trialClinical Breast Cancer.  11:82-92. 2011
    2010 Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancerClinical Breast Cancer.  10:281-287. 2010
    2010 Pilot trial of preoperative (Neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancerClinical Breast Cancer.  10:275-280. 2010
    2010 A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancerCancer Investigation.  28:208-215. 2010
    2010 Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)Cancer Biotherapy and Radiopharmaceuticals.  25:13-19. 2010
    2010 Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancerJournal of Thoracic Oncology.  5:1977-1985. 2010
    2009 Analysis of the impact and burden of illness of adult chronic ITP in the USCurrent Medical Research and Opinion.  25:2961-2969. 2009
    2009 Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphomaJournal of Clinical Oncology.  27:5023-5030. 2009
    2009 High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responsesJournal of Clinical Oncology.  27:4754-4759. 2009
    2009 A randomized, phase II trial of two dose schedules of carboplatin/ paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)Annals of Oncology.  20:1068-1073. 2009
    2009 Data-driven medical decision-making in managing chemotherapy-induced nausea and vomitingCommunity Oncology.  6:62-67. 2009
    2009 Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: Results from a community oncology practiceCommunity Oncology.  6:257-261. 2009
    2007 Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxelInvestigational New Drugs.  25:565-570. 2007
    2007 Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpuraNew England Journal of Medicine.  357:2237-2247. 2007
    2007 Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigatorsJournal of Clinical Oncology.  25:669-674. 2007
    2007 Bendamustine in non-Hodgkin lymphoma: The double-agent that came from the cold war 2007
    2006 Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromesJournal of Clinical Oncology.  24:2456-2464. 2006
    2005 Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer 2005
    2005 Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancerJournal of Clinical Oncology.  23:9089-9096. 2005
    2004 Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progressionJournal of Clinical Oncology.  22:1063-1070. 2004
    2004 Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myelomaBritish Journal of Haematology.  125:470-476. 2004
    2003 Monoclonal antibody therapy of non-Hodgkin's lymphoma: the Rituximab story.Journal of the Medical Association of Georgia.  92:39-46. 2003
    2002 A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumorsClinical Cancer Research.  8:3092-3099. 2002
    2002 Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphomaJournal of Clinical Oncology.  20:3262-3269. 2002
    2002 Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trialBlood.  99:4336-4342. 2002
    2002 Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-hodgkin's lymphomaSeminars in Oncology.  29:87-92. 2002
    2001 A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti αvβ3) antibody in patients with metastatic cancerCancer Biotherapy and Radiopharmaceuticals.  16:125-132. 2001
    2001 Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomasJournal of Clinical Oncology.  19:3918-3928. 2001
    2001 Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancerJournal of Clinical Oncology.  19:3234-3243. 2001
    2001 Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapyAnnals of Oncology.  12:109-114. 2001
    2000 A pilot study of anti-cd20 moab mtuximab in patients with refractory immune thrombocytopenic purpura (TTP)Blood.  96. 2000
    2000 BR96-doxorubicin: Been there, done that! [1] (multiple letters)Journal of Clinical Oncology.  18:4000. 2000
    2000 Oral chlorambucil and prednisone with rituximab as initial chemotherapy for low grade non hodgkin's lymphoma: a phase ii trialBlood.  96. 2000
    2000 Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomasJournal of Clinical Oncology.  18:1316-1323. 2000
    2000 Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumorsJournal of Clinical Oncology.  18:2282-2292. 2000
    1999 Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: Comparison of intradermal versus subcutaneous administrationClinical Cancer Research.  5:2330-2337. 1999
    1999 NCCN practice guidelines for Hodgkin's disease 1999
    1999 Combined modality therapy of A431 human epidermoid cancer using anti- EGFR antibody C225 and radiationCancer Biotherapy and Radiopharmaceuticals.  14:451-463. 1999
    1999 Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancerJournal of Clinical Oncology.  17:478-484. 1999
    1999 Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapyJournal of Clinical Oncology.  17:268-276. 1999
    1998 Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interkeukin-2Blood.  91:399-405. 1998
    1998 Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoidesJournal of The American Academy of Dermatology.  39:63-73. 1998
    1998 Chimeric antibodies with specificity for tumor antigens: Demonstration of in situ localization to tumors after antibody therapy 1998
    1998 Diphtheria toxin fusion proteinsCurrent Topics in Microbiology and Immunology.  234:63-81. 1998
    1998 Immunologic response to the dual murine anti-id vaccine melimmune-1 and melimmune-2 in patients with high-risk melanoma without evidence of systemic diseaseJournal of Immunotherapy.  21:379-388. 1998
    1997 A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrowHuman Gene Therapy.  8:157-170. 1997
    1997 Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trialsCancer Biotherapy and Radiopharmaceuticals.  12:79-87. 1997
    1996 Phase Ia/Ib trial of Anti-GD2 chimeric monoclonal antibody 14.18 (ch l4.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanomaJournal of Immunotherapy.  19:206-217. 1996
    1995 Phase II Trial of Murine Monoclonal Antibody D612 Combined with Recombinant Human Monocyte Colony-stimulating Factor (rhM-CSF) in Patients with Metastatic Gastrointestinal CancerCancer Research.  55:4339-4346. 1995
    1995 CD16+ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factorBlood.  85:2910-2917. 1995
    1995 Phase I trial of an anti-cd19 deglycosylated ricin a chain immunotoxin in non-hodgkin's lymphoma: Effect of an intensive schedule of administrationJournal of Immunotherapy.  18:231-241. 1995
    1993 A Phase I Clinical Trial of Murine Monoclonal Antibody D612 in Patients with Metastatic Gastrointestinal CancerCancer Research.  53:4555-4562. 1993
    1993 Generation of a human anti-idiotypic antibody that mimics the GD2 antigenJournal of Immunology.  151:3390-3398. 1993
    1992 Frequent anti-V-region immune response to mouse B72.3 monoclonal antibodyJournal of Clinical Immunology.  12:116-121. 1992
    1992 Advances in monoclonal antibody therapy of cancerAmerican Journal of the Medical Sciences.  304:214-224. 1992
    1992 Monoclonal antibody therapy of cancer 1992
    1992 Phase I Trial of the Murine Monoclonal Anti-GD2 Antibody 14G2a in Metastatic MelanomaCancer Research.  52:4342-4347. 1992
    1992 Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancerJournal of Nuclear Medicine.  33:23-29. 1992
    1992 Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanomaHuman Antibodies.  3:19-24. 1992
    1992 Selection of platelets for refractory patients by HLA matching and prospective crossmatchingTransfusion.  32:633-640. 1992
    1991 Pharmacokinetics and Immune Response of 131I-ChimericMouse/Human B72.3 (Human 74) Monoclonal Antibody in HumansCancer Research.  51:5461-5466. 1991
    1991 Evidence for the Elevation of Serum Carcinoembryonic Antigen and Tumor-associated Glycoprotein-72 Levels in Patients Administered InterferonsCancer Research.  51:4155-4163. 1991
    1991 In-111 labeled monoclonal anti-carcinoembryonic antigen antibody (ZCE025) in the immunoscintigraphic imaging of metastatic antigen-producing adenocarcinomasClinical Nuclear Medicine.  16:110-116. 1991
    1991 Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibodyJournal of Nuclear Medicine.  32:1162-1168. 1991
    1990 A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: Clinical and immunological data 1990
    1990 Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humansJournal of biological response modifiers.  9:178-184. 1990
    1990 Intravenous immunoglobulin therapy in systemic lupus erythematosus‐associated thrombocytopeniaArthritis and Rheumatism.  33:1233-1239. 1990
    1989 Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopeniaBlood.  73:662-665. 1989
    1989 Intrathecal cytosine arabinoside-induced acute, rapidly reversible paralysisAmerican Journal of Medicine.  86:729-730. 1989
    1989 Monocyte-platelet interaction in immune and nonimmune thrombocytopeniaBlood.  74:1328-1331. 1989
    1989 Quinidine-induced immune thrombocytopeniaHenry Ford Hospital medical journal.  37:28-32. 1989
    1988 Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects 1988
    1988 Phase I trial of multiple large doses of murine monoclonal antibody Co17-1A. II. Pharmacokinetics and immune response 1988
    1988 Clinical use of a standard kit-preparation of radiolabeled monoclonal antibody 96.5 in the diagnostic imaging of metastatic melanomaJournal of Clinical Oncology.  6:1059-1065. 1988
    1988 Effect of commercial immunoglobulin G preparation on human monocyte Fc-receptor dependent binding of antibody coated plateletsBritish Journal of Haematology.  68:47-51. 1988
    1987 Acute myelofibrosis and multiple chloromas of the mandible and skinInternational Journal of Oral and Maxillofacial Surgery.  16:108-111. 1987
    1987 Immune thrombocytopenia: Effects of maternal gamma globulin infusion on maternal and fetal serum, platelet, and monocyte IgG: Case ReportAmerican Journal of the Medical Sciences.  293:112-118. 1987
    1987 Platelet surface-bound IgG in patients with immune and nonimmune thrombocytopeniaBlood.  69:278-283. 1987
    1986 Phase I clinical trial of CO17-1A monoclonal antibodyHybridoma.  5. 1986
    1986 In vitro effects of gammaglobulin (IgG) on human monocyte Fc receptor function. I. Effect on monocyte membrane‐associated IgG and Fc receptor‐dependent binding of antibody‐coated plateletsAmerican Journal of Hematology.  23:197-207. 1986

    Chapter

    Year Title Altmetric
    2013 CDX-011 (Glembatumumab vedotin, CR011-vcMMAE).  211-220. 2013

    Research Overview

  • Phase I trials, Clinical Translational Research
  • Principal Investigator On

  • A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAC) Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC--T) as Adjuvant Treatment of Operable Breast Cancer HER2Neu Negative Patients with Positive Axillary Lymph Nodes  awarded by BREAST CANCER INTERNATIONAL RESEARCH GROUP
  • Comprehensive Cancer Center Core Support Grant - Administrative Supplement to Support Participation in the Experimental Therapeutics Clinical Trials Network (ETCTN)  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Early Phase Clinical Research  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Early Phase Clinical Research  awarded by National Cancer Institute/NIH/DHHS
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by AILERON THERAPEUTICS
  • Private Grant  awarded by MIRATI THERAPEUTICS, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by ASTELLAS PHARMA US, INC.
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by ROCHE TCRC, INC.
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • School of Medicine Clinical Investigator Training Program  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • Investigator On

  • Center for Clinical and Translational Science (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Protocol Review and Monitoring System  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Protocol Review and Monitoring System  awarded by National Cancer Institute/NIH/DHHS
  • Overcoming PAAP Inhibitor Resistance of BACA-Deficient Ovarian Cancers  awarded by DOD - Department of Defense
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC.
  • Private Grant  awarded by AILERON THERAPEUTICS
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by HEAT BIOLOGICS
  • Private Grant  awarded by CELSION CORPORATION
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by KALA PHARMACEUTICALS, INC.
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS
  • Private Grant  awarded by AFFIMED GMBH
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by FORTY SEVEN, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by MINNEAMRITA THERAPEUTICS, LLC ^
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by SYROS PHARMACEUTICALS INC.
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by DECIPHERA PHARMACEUTICALS. LLC
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by FORTY SEVEN, INC.
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS
  • Private Grant  awarded by MedImmune
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by ONO PHARMACEUTICAL COMPANY LTD
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by SKYLINE BIOSCIENCES LLC
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS
  • Education And Training

  • Henry Ford Hospital, Internship
  • Henry Ford Hospital, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, Heidelberg University 1980
  • Full Name

  • Mansoor Saleh